Abstract 1425P
Background
Timely diagnosis with complete molecular profiling is essential in advanced lung cancer. Although tissue sampling remains the gold standard, liquid biopsies provide an alternative option for timely molecular characterization, especially for epidermal growth factor receptor (EGFR) testing in lung cancer.
Methods
All patients referred at the Centre Hospitalier de l’Université de Montréal (CHUM) with a radiological suspicion of advanced lung cancer and no known prior tumour molecular testing were prospectively screened and consented. Plasma and tissue samples were retrieved for EGFR testing and mutations were analyzed using Cobas® cell-free DNA (cfDNA). The CLEAR study evaluated plasma and tissue EGFR testing and the clinical impact on the management of suspected lung cancer patients.
Results
Between November 2019 and January 2023, a total of 312 patients were initially screened for eligibility for inclusion in the study and 7 patients were excluded for history of treated lung cancer. Median age was 68 years, 55% were female, 17% were non-smokers, and 30% were active smokers. 83% had non-small cell lung cancer and 70% of patients had stage IV disease. 8% and 10% EGFR mutations were detected by cfDNA and tissue biopsy, respectively. EGFR exon 19 deletion was the most frequent mutation, detected in 59% of patients. Median time to EGFR result was 28 days and 3 days for tissue and plasma sampling, respectively. cfDNA was 100% specific and 72% sensitive for EGFR status. Positive predictive value was 100% and the negative predictive value was 95%. Osimertinib was initiated within a median of 12 days of cfDNA results and up to 21 days before tissue results. Cranial radiotherapy was avoided in 6 EGFR-positive patients with brain metastases.
Conclusions
Early detection of EGFR mutations by cfDNA reduces time to diagnosis and accelerates therapy initiation. Cobas® assay is specific, with high positive and negative predictive values. Decreased delays to access targeted therapy can decrease improper treatment choices and alleviate complications of untreated disease while awaiting molecular results from tissue biopsies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca.
Disclosure
Y. Kim, I. Syed, N. Devost, G. Kenth: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. D. Hui: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. N. Blais: Financial Interests, Personal, Funding: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1443P - Patient-reported outcomes (PROs) with cemiplimab plus chemotherapy (CEMI + CHEMO) for first-line treatment of advanced non-small cell lung cancer (aNSCLC): PD-L1 level subgroups in EMPOWER-Lung 3
Presenter: Miranda Gogishvili
Session: Poster session 20
1444P - Sintilimab with two cycles nab-paclitaxel / platinum as first line therapy for advanced squamous non-small-cell lung cancer: The final analysis and biomarker results
Presenter: Huijuan Wang
Session: Poster session 20
1445P - A randomized phase III trial on Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN), results of the interim analysis
Presenter: Ilias Houda
Session: Poster session 20
1447P - IMscin001 part 2 updated results: Efficacy, safety, immunogenicity and patient-reported outcomes (PROs) from the randomised phase III study of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Presenter: Mauricio Burotto
Session: Poster session 20
1449P - The preliminary data from a single-arm, open-label, multicenter phase II clinical trial: KN046 combined with axitinib as first-line (1L) treatment for NSCLC
Presenter: Yuanyuan Zhao
Session: Poster session 20
1450P - Addition of bevacizumab to first-line chemoimmunotherapy in NSCLC with liver metastases
Presenter: Matthieu Roulleaux Dugage
Session: Poster session 20
1451P - Identifying long-term responders to immune checkpoint blockade: Potential utility of serum proteomic profiling in metastatic non-small cell lung cancer
Presenter: Rafael Bach Mora
Session: Poster session 20
1452P - Factors associated with real-world (rw) outcomes among pts with metastatic NSCLC (mNSCLC) receiving select immuno-oncology (IO) regimens: CORRELATE
Presenter: Stephen Liu
Session: Poster session 20